title: Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
abstract: Influenza B strains represent on average 23% of all circulating strains in Europe and when there is a vaccine mismatch on B strains, additional influenza-related hospitalizations and deaths as well as substantial additional costs are observed. The objective was to estimate the public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines (QIV) compared to trivalent influenza vaccines (TIV) in Europe (EU). Based on data from 5 EU countries (France, Germany, Italy, Spain and UK) during 10 influenza seasons from 2002 to 2013, epidemiological and associated economic outcomes were estimated for each season for the actual scenario where the TIV was used, and for a hypothetical scenario where QIV could have been used instead. By using QIV, this study estimated that for the 5 EU countries, an additional 1.03 million (327.9/100,000 inhabitants) influenza cases, 453,000 (143.9/100,000) general practitioners consultations, 672,000 (213.1/100,000) workdays lost, 24,000 (7.7/100,000) hospitalizations and 10,000 (3.1/100,000) deaths could have been avoided compared to the use of TIV over the 10-seasons-period. This study estimates that QIV can be of economic value since from a societal perspective 15 million Euros would have been saved on general practitioners consultations (14 million Euros from third-party payer perspective), 77 million on hospitalizations (74 million Euros from third-party payer perspective) and 150 million Euros on workdays lost, across the 5 EU countries. In conclusion, the present study estimates that, compared to TIV, QIV may result in a substantial decrease in epidemiological burden and in influenza-related costs.
authors.affiliation: a Sanofi Pasteur MSD, Market Access and Health Outcomes , Lyon , France.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Uhart
authors.affiliation: b Sanofi Pasteur MSD , Epidemiology Department , Lyon , France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Bricout
authors.affiliation: c Creativ-Ceutical, Health Economics and Outcomes Research , Paris , France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Clay
authors.affiliation: a Sanofi Pasteur MSD, Market Access and Health Outcomes , Lyon , France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Largeron
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines
keywords: Europe; epidemiology; immunization programs; influenza vaccines; public health